Systemic chemotherapy and new experimental approaches in the treatment of metastatic prostate cancer

Annals of Oncology

Volumn 19, Issue SUPPL. 7, 2008, Pages

  Sternberg, C N ^a  

^a SAN CAMILLO FORLANINI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABIRATERONE; AFLIBERCEPT; ANDROGEN RECEPTOR; ANTIHYPERTENSIVE AGENT; ATRASENTAN; BEVACIZUMAB; CALCITRIOL; CB 7630; CORTICOSTEROID; DASATINIB; DENOSUMAB; DOCETAXEL; ENDOTHELIN 1; ENZYME INHIBITOR; EPLERENONE; ESTRAMUSTINE; GONADORELIN AGONIST; MITOXANTRONE; N (3 METHOXY 5 METHYL 2 PYRAZINYL) 2 [4 (1,3,4 OXADIAZOL 2 YL)PHENYL] 3 PYRIDINESULFONAMIDE; OSTEOCLAST DIFFERENTIATION FACTOR; PLACEBO; POTASSIUM; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROTEIN TYROSINE KINASE; SATRAPLATIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VITAMIN D RECEPTOR; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; TAXOID;

BONE METASTASIS; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE FREE SURVIVAL; DRUG FATALITY; DRUG TARGETING; ENZYME INHIBITION; FLUID RETENTION; HEMATOLOGIC DISEASE; HUMAN; HYPERTENSION; HYPOKALEMIA; LOW DRUG DOSE; MALE; METASTASIS POTENTIAL; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; SIDE EFFECT; TREATMENT OUTCOME; ARTICLE; DRUG DELIVERY SYSTEM; METASTASIS; PATHOLOGY; PROSTATE TUMOR;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG DELIVERY SYSTEMS; HUMANS; MALE; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 53449095783     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn473     Document Type: Conference Paper

References (44)

1. Berthold DR, Sternberg CN, Tannock IF. Management of Advanced Prostate Cancer after First-Line Chemotherapy. J Clin Oncol 2005; 23: 8247-8452.
2. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512.
3. Kantoff PW, Halabi S, Conaway M et al. Hydrocortisone with or without mitoxantrone in men with hormone refractory prostate cancer: Results of Cancer and Leukemia Group B 9182 study. J Clin Oncol 1999; 17: 2506-2513.
4. Petrylak DP, Tangen CM, Hussain MH et al. Docetaxel and estramustine. compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520.
5. Berthold DR, Pond GR, Soban F et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. J Clin Oncol 2008; 26: 242-245.
6. Armstrong AJ, Garrett-Mayer ES, Yang YC et al. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: A TAX327 study analysis. Clin Cancer Res 2007; 13: 6396-6403.
7. Shah RB, Mehra R, Chinnaiyan AM et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: Lessons from a rapid autopsy program. Cancer Res 2004; 64: 9209-9216.
8. Petrylak DP, Ankerst DP, Jiang CS et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 2006; 98: 516-521.
9. Berthold DR, Pond GR, Roessner M et al. Treatment of Hormone-Refractory Prostate Cancer with Docetaxel or Mitoxantrone: Relationships between PSA, Pain and Quality of Life Response and Survival in the Tax-327 Study. Clin Cancer Res 2008; 14: 2763-2767.
10. Scher HI, Halabi S, Tannock I et al. Design and Endpoints of Clinical Trials for Patients with Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group (PCWG2). J Clin Oncol 2008; 26: 1148-1159.
11. Bergers G, Benjamin LE. Tumorigenesis and the anglogenic switch. Nat Rev Cancer 2003; 3: 401-410.
12. Jimenez JA, Kao C, Raikwar S, Gardner TA. Current status of anti-angiogenesis therapy for prostate cancer. Urol Oncol 2006; 24: 260-268.
13. Bok RA, Halabi S, Fei DT et al. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: A cancer and leukemia group B study. Cancer Res 2001; 61: 2533-2536.
14. Weidner N, Carroll PR, Flax J et al. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 1993; 143: 401-409.
15. Shariat SF, Anwuri VA, Lamb DJ et al. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy. J Clin Oncol 2004; 22: 1655-1663.
16. Borre M, Nerstrom B, Overgaard J. Association between immunohistochemical expression of vascular endothelial growth factor (VEGF), VEGF-expressing neuroendocrine-differentiated tumor cells, and outcome in prostate cancer patients subjected to watchful waiting. Clin Cancer Res 2000; 6: 1882-1890.
17. Kohli M, Kaushal V, Spencer HJ, Mehta P. Prospective study of circulating angiogenic markers in prostate-specific antigen (PSA)-stable and PSA-progressive hormone-sensitive advanced prostate cancer. Urol 2003; 61: 765-769.
18. Picus J, Halabi S, Rini B. The use of bevacizumab (B) with docetaxel (D) and estramustine (E) in hormone refractory prostate cancer (HRPC): Initial results of CALGB 90006. Proc Annu Meet Am Soc Clin Oncol 2003: 22: (Abstr).
19. Ryan CJ, Lin AM, Small EJ. Angiogenesis inhibition plus chemotherapy for metastatic hormone refractory prostate cancer: History and rationale. Urol Oncol 2006; 24: 250-253.
20. Verheul HM, Hammers H, van Erp K et al. Vascular endothelial growth factor trap blocks tumor growth, metastasis formation, and vascular leakage in an orthotopic murine renal cell cancer model. Clin Cancer Res 2007; 13: 4201-4208.
21. Nelson JB, Hedican SP, George DJ et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995; 1: 944-949.
22. Yin JJ, Mohammad KS, Kakonon SM et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA 2003; 100: 10954-10949.
23. Pirtskhalaishvili G, Nelson JB. Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate 2000; 44: 77-87.
24. Thakkar SG, Choueiri TK, Garcia JA, Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics. Curr Oncol Rep 2006; 8: 108-113.
25. Carducci MA, Jimeno A. Targeting bone metastasis in prostate cancer with endothelin receptor antagonists. Clin Cancer Res 2006; 12: 6296s-6300s.
26. Carducci MA, Padley RJ, Breul J et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: A randomized, phase II, placebo-controlled trial. J Clin Oncol 2003; 21: 679-689.
27. Vogelzang NJ, Nelson JB, Schulman C et al. Meta-analysis of Clinical Trials of Atrasentan 10 mg in Metastatic Hormone-Refractory Prostate Cancer. J Clin Oncol 2005; 23: 4563.
28. Lipton A, Sleep DJ, Hulting SM et al. Benefit of Atrasentan in Men with Hormone Refractory Prostate Cancer Metastatic to Bone. J Clin Oncol 2004; 22: 4687.
29. Sleep DJ, Nelson JB, Petrylak DP et al. Clinical benefit of atrasentan for men with metastatic hormone-refractory prostate cancer metastatic to bone. J Clin Oncol 2006; 24: 4630.
30. Morris CD, Rose A, Curwen J et al. Specific inhibition of the endothelin A receptor with ZD4054: Clinical and pre-clinical evidence. Br J Cancer 2005; 92: 2148-2152.
31. James NO, Borre M, Zonnenberg B et al. ZD4054, a potent, specific endothelin A receptor antagonist, improves overall survival in pain-free or mildly symptomatic patients With hormone-resistant prostate cancer (HRPC) and bone metastases. Eur J Cancer 2007 (Suppl 5): (Abstract).
32. Beer TM, ASCENT: The androgen-independent prostate cancer study of calcitriol enhancing taxotere. BJU Int 2005; 96: 508-513.
33. Beer TM, Ryan CW, Venner PM et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: A report from the ASCENT Investigators. J Clin Oncol 2007; 25: 669-674.
34. Nam S, Kim D, Chong JQ et al. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 2008; 65: 9185-9189.
35. Castoria G, Lombardi M, Barone MV et al. Rapid signalling pathway activation by androgens in epithelial and stromal cells. Steroids 2004; 69: 517-522.
36. Sternberg CN, Whelan P, Hetherington J et al. Phase III Trial of Satraplatin, an Oral Platinum plus Prednisone vs. Prednisone Alone in Patients with Hormone Refractory Prostate Cancer. Oncology 2005; 68: 2-9.
37. Sternberg CN, Petrylak D, Witjes F et al. Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: Results of a randomized phase III trial. Proc Annu Meet Am Soc Clin Oncol 2007; 25: (Abstr).
38. Mohler JL, Gregory CW, Ford OH et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 2004; 10: 440-448.
39. Stigliano A, Gandini O, Cerquetti L et al. Increased metastatic lymph node 64 and CYP17 expression are associated with high stage prostate cancer. J Endocrinol 2007; 194: 55-61.
40. Attard G, Reid A, Barrett M et al. Inhibition of androgen synthesis results in a high response rate in castration refractory prostate cancer. AACR Annual Meeting 48 2007: (Abstr).
41. Ryan CJ, Rosenberg J, Lin A et al. J. Phase I evaluation of abiraterone acetate (CB7630), a 17 alpha hydroxylase C17,20-Lyase inhibitor in androgen-independent prostate cancer (AiPC). Proc Annu Meet Am Soc Clin Oncol 25 2007; 18S: (Abstr).
42. Dougall WC, Chaisson M. The RANK(RANKL/OPG triad in cancer-induced bone diseases. Cancer Metastasis Rev 2006; 25: 541-549.
43. Lynch CC, Hikosaka A, Acuff HB et al. MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell 2005; 7: 485-496.
44. Yu EY, Wilding G, Posadas E et al. Dasatinib in patients with hormone-refractory progressive prostate cancer: A phase II study. J Clin Oncol 2008; 26: (May 20 suppl; abstr 5156).